A Dose Ascending, Study To Examine The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of GSK233705B.
A Dose Ascending, Study To Examine The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of GSK233705B.
NCT ID: NCT00453479 Phase: PHASE2 Status: COMPLETED Enrollment: 23 Completion: 2007-10-11
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
GSK233705B
Summary
GSK233705 is a high-affinity specific muscarinic receptor (mAChR) antagonist which is being developed for the treatment of chronic obstructive pulmonary disease. This is a randomised, double-blind, placebo-controlled, dose ascending, parallel group study to examine the safety, tolerability, pharmacokinetics and pharmacodynamics of twice daily inhaled doses of GSK233705B for 7 days, in COPD subjects.
Primary Outcome
Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)